With an FDA approval decision on treosulfan possibly more than a year off, the U.S. Patent and Trademark Office granted Medac GmbH a third one-year extension of its method-of-use patent covering the drug, which is being developed as a conditioning agent in allogeneic hematopoietic stem cell transplantation.
Monte Rosa Therapeutics Inc. has cut a deal with Roche Holding AG that brings the molecular glue degrader-based medicines developer an up-front $50 million and the possibility of more than $2 billion in milestone payments. The Boston-based company coupled the deal by releasing positive interim data from the phase I dose-escalation portion of its phase I/II open-label, multisite study of MRT-2359 in Myc-driven solid tumors.
Abbisko Therapeutics Co. Ltd. announced positive first-in-human data for its highly selective fibroblast growth factor receptor (FGFR) 4 inhibitor, irpagratinib (ABSK-011), for treating advanced hepatocellular carcinoma with FGF19 overexpression, which is seen in roughly 30% of liver cancers.
New and updated clinical data presented by biopharma firms at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
, including: Aprea, Aulos, Avistone, Beyond Cancer, Black Diamond, Cogent, Omega, Ose, Puma, Revolution, Verastem.
Cancer treatments for targeting tumor amplifications lag behind those targeting point mutations – and part of the reason may be that amplifications often reside on extrachromosomal DNA (ecDNA). Since ecDNA was first described back in 1965 as minute chromatin bodies in brain cancer cells, the use of large-scale DNA sequencing techniques has revealed the presence of ecDNA across a wide range of cancer types. “The circular structure of ecDNA is associated with increased proto-oncogenic capacity in comparison to linear amplifications. Another key feature is that ecDNA does not contain centromeres,” Roel Verhaak, from Yale School of Medicine, told the audience in a session at the 2023 AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics in Boston.
Precision cancer biotech Abion Inc. announced a positive interim phase II readout for ABN-401, its novel c-mesenchymal-epithelial transition (c-MET)-targeting tyrosine kinase inhibitor (TKI) for advanced non-small-cell lung cancer (NSCLC), lighting a runway to its next trial as a combination regimen.
In its first significant partnering deal since being founded in 2020, Medilink Therapeutics Co. Ltd. licensed exclusive global rights to an antibody-drug conjugate (ADC) targeting HER3 to Biontech SE in exchange for an up-front payment of $70 million, with the possibility for additional payments tied to development, regulatory and commercial milestones exceeding $1 billion. Medilink retains rights in mainland China, Hong Kong Special Administrative Region and Macau Special Administrative Region.
Tempest Therapeutics Inc. has begun the hunt for a phase III partner to help reach the market with TPST-1120, the oral selective peroxisome-proliferator activated receptor-alpha (PPAR-alpha) antagonist that showed clinical superiority on multiple study endpoints in phase Ib/II as an add-on in first-line unresectable or metastatic hepatocellular carcinoma (HCC).
Arbele Ltd. founder and CEO John Luk identified and patented cadherin-17 as a therapeutic cancer target, and the company was founded to develop immunotherapies for gastrointestinal cancers, which are prevalent in Asia Pacific.
Just as Wall Street had begun mulling the possible fallout of the regulatory vote against full U.S. FDA clearance for Amgen Inc.’s KRAS G12C therapy for non-small-cell lung cancer, a new – albeit not entirely unexpected – development cropped up in the space. Mirati Therapeutics Inc. disclosed Oct. 9 that Bristol Myers Squibb Co. (BMS) is offering to take over the firm in a deal that could be worth as much as $5.8 billion, historically one of the larger takeovers for 2023.
RSS
